Trump signs order fast-tracking FDA review of psychedelics for mental health
President Trump signed an executive order Saturday directing the FDA to expedite review of psychedelic drugs including psilocybin, MDMA, LSD and ibogaine for treating mental health conditions like depression, PTSD and anxiety. The order allocates fifty million dollars to states developing psychedelic treatment programs and directs the FDA to issue priority review vouchers for three psychedelics next week, potentially cutting approval timelines from months to weeks. The move addresses a stated mental health crisis affecting fourteen million American adults with serious mental illness. Notably, no psychedelic has yet been approved in the U.S., though several are undergoing large-scale clinical trials. Safety concerns remain prominent, particularly around ibogaine's known cardiovascular risks, which have been linked to over thirty deaths in medical literature. The order also establishes pathways for terminally ill patients to access investigational drugs under right-to-try provisions and directs the DEA and Department of Justice to begin rescheduling reviews after successful Phase 3 trials.
Key facts
- Trump allocated $50 million in federal funds to states developing psychedelic treatment programs
- FDA will issue priority review vouchers for three psychedelics next week, potentially accelerating approval timelines from months to weeks
- 14 million American adults have serious mental illness according to the executive order
- Ibogaine is linked to more than 30 deaths in medical literature and can cause irregular heart rhythms
- No psychedelic has been approved in the United States, though psilocybin, MDMA and LSD are in clinical trials
- Department of Veterans Affairs is participating in at least five psychedelic trials across New York, California and Oregon
How different outlets framed it
Right-leaning coverage: Conservative outlets including Fox News framed the order as addressing veteran suicide and mental health crisis, celebrating the fast-track pathway and Trump's action as decisive leadership. They quoted doctors supporting psychedelic research potential and emphasized benefits for veterans with treatment-resistant PTSD, while still acknowledging safety protocols and monitoring requirements.
Limits of this briefing
While multiple mainstream news outlets covered the order, few left-leaning sources offered distinct critical perspectives on the order itself. Additionally, coverage was limited on how psychedelic-assisted therapy would be delivered, funded through insurance, or made accessible beyond research settings. The long-term effectiveness and real-world safety profiles remain uncertain.
Sources
- NPR: Trump signs order fast tracking review of psychedelics for mental health disorders Centre
- PBS NewsHour: Trump signs order to hasten review of psychedelics Centre
- CNN: Trump signs executive order urging more research into ibogaine and other psychedelics Centre
- Fox News: Trump-backed plan could fast-track psychedelic therapies Right
- STAT News: How Trump is pushing psychedelics reform through the health agencies Centre